Skip to main content

Table 1 Baseline characteristics according to the sorafenib response

From: Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

Variable

All (n = 124)

Non-PD (n = 44)

PD (n = 80)

P

Age (year)

61 ± 11

62 ± 10

61 ± 12

0.707

Sex, N (%)

107 (86.3)

36 (81.8)

71 (88.8)

0.423

ECOG performance status 0, N (%)

112 (90.3)

42 (95.5)

70 (87.5)

0.210

Etiology, N (%)

   

0.02

 HBV

91 (73.4)

26 (59.1)

65 (81.2)

 

 HCV

21 (16.9)

10 (22.7)

11 (13.8)

 

 Alcohol

12 (9.7)

8 (18.2)

4 (5)

 

Body mass index (kg/m2)

22.3 ± 3.1

23.1 ± 3.2

21.9 ± 3.0

0.052

Macrovascular invasion, N (%)

39 (31.5)

11 (25.0)

28 (35.0)

0.344

Extrahepatic spread, N (%)

53 (42.7%)

16 (36.4)

37 (46.2)

0.382

BCLC stage C, N (%)

83 (66.9%)

25 (56.8)

58 (72.5)

0.185

Child-Pugh score, N (%)

   

0.492

 5

114 (91.9)

42 (95.5)

72 (90)

 

 6

10 (8.1)

2 (4.5)

8 (10)

 

MELD

8.8 ± 2.2

8.36 ± 1.54

8.96 ± 2.47

0.1

Albumin (g/dL)

3.79 ± 0.42

3.78 ± 0.46

3.81 ± 0.41

0.739

Total bilirubin (mg/dL)

1.06 ± 0.50

0.99 ± 0.47

1.09 ± 0.51

0.273

Prothrombin time (INR)

1.14 ± 0.10

1.13 ± 0.09

1.15 ± 0.1

0.299

Creatinine (mg/dL)

0.89 ± 0.56

0.87 ± 0.13

0.9 ± 0.69

0.705

Platelet (×103/μL)

122 (17–787)

113 (17–291)

128 (52–787)

0.006

Alpha-fetoprotein (ng/mL)

128.8 (1.3–730,000)

114.7 (2.6–226,100)

152.2 (1.3–730,000)

0.187

PIVKA-II (mAU/mL)

109.5 (12–339,858)

25.5 (12–25,884)

351 (15–339,858)

0.003

Angiopoietin 2 (ng/mL)

2962.7 (1099.4–12,907.8)

2762.2 (1289.6–8360.4)

3026.9 (1099.4–12,907.8)

0.109

CD117 (ng/mL)

3.76 (1.01–226.85)

3.36 (1.01–10.23)

3.87 (1.10–226.85)

0.234

bFGF (pg/mL)

2.38 (0–61.57)

1.65 (0–14.62)

3.07 (0.43–61.57)

< 0.001

HGF (pg/mL)

1781.9 (913.9–6116.0)

1605.7 (913.9–4152.4)

1965.2 (1020.3–6117.0)

0.056

LOXL2 (ng/mL)

0.816 (0.034–4.007)

0.718 (0.034–4.007)

0.850 (0.039–3.765)

0.792

PDGFRb (pg/mL)

2045.6 (647.5–22,904.5)

2087.9 (777.7–22,904.5)

1965.3 (647.5–8214.9)

0.419

sVEGFR1 (ng/mL)

0.16 (0.04–13.65)

0.16 (0.06–13.65)

0.14 (0.04–0.53)

0.314

AAR

1.29 (0.58–11.6)

1.31 (0.58–2.67)

1.29 (0.61–11.6)

0.105

APRI

1.01 (0.17–6.54)

1.17 (0.17–4.54)

0.95 (0.17–6.54)

0.847

FIB-4

4.0 (0.6–21.0)

4.4 (0.9–21.0)

3.6 (0.6–12.3)

0.161

Lok index

0.66 ± 0.24

0.67 ± 0.24

0.65 ± 0.24

0.68

P2/MS

29.6 (0.46–1060.7)

27.3 (0.5–202.4)

36.7 (6.2–1060.7)

0.102

  1. Values are expressed as mean ± standard deviation, medians (ranges), or frequencies (percentages)
  2. Abbreviations: PD, progressive disease, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4